I am thinking that to become the standard of care, B needs to be "non-inferior" to daptomycin. Then the extra benefits of single dose, lower resistance and lower threat of resistance really can multiply the potential. I am optimistic about the trial, but it is not without risk.
Wild-I don't think there have been any changes made to B for this trial besides dosage level and frequency...
Market Data 
Markets 
AI
